The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Selection and evaluation of clinically relevant AAV variants in a xenograft liver model
Open accessAbstract
Recombinant adeno-associated viral (rAAV) vectors have shown early promise in clinical trials. The therapeutic transgene cassette can be packaged in different AAV capsid pseudotypes, each having a unique transduction profile. At present, rAAV capsid serotype selection for a specific clinical trial is based on effectiveness in animal models. However, preclinical animal studies are not always predictive of human outcome. Here, in an attempt to further our understanding of these discrepancies, we used a chimaeric human-murine liver model to compare directly the relative efficiency of rAAV transduction in human versus mouse hepatocytes in vivo. As predicted from preclinical and clinical studies, rAAV2 vectors functionally transduced mouse and human hepatocytes at equivalent but relatively low levels. However, rAAV8 vectors, which are very effective in many animal models, transduced human hepatocytes rather poorly-approximately 20 times less efficiently than mouse hepatocytes. In light of the limitations of the rAAV vectors currently used in clinical studies, we used the same murine chimaeric liver model to perform serial selection using a human-specific replication-competent viral library composed of DNA-shuffled AAV capsids. One chimaeric capsid composed of five different parental AAV capsids was found to transduce human primary hepatocytes at high efficiency in vitro and in vivo, and provided species-selected transduction in primary liver, cultured cells and a hepatocellular carcinoma xenograft model. This vector is an ideal clinical candidate and a reagent for gene modification of human xenotransplants in mouse models of human diseases. More importantly, our results suggest that humanized murine models may represent a more precise approach for both selecting and evaluating clinically relevant rAAV serotypes for gene therapeutic applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“AAV-NP59 also elicited reduced anti-AAV IgG than AAV-LK03 (119) and AAV8, but not as good as previously discovered engineer capsid AAV-DJ.”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [119]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Organoid Models and Applications in Biomedical Research
Xinaris, C., Brizi, V., & Remuzzi, G. (2015) · The Nephron journals/Nephron journals · doi:10.1159/000433566 · Cited by 3,519
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationEffect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Self-citationKay, M. A., Manno, C. S., Ragni, M. V., Larson, P. J., Couto, L. B., McClelland, A., Glader, B. E., Chew, A. K., Tai, S. J., Herzog, R. W., et al. (2000) · Nature Genetics · doi:10.1038/73464 · Cited by 1,019
Self-citationBoutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970
Robust expansion of human hepatocytes in Fah−/−/Rag2−/−/Il2rg−/− mice
Azuma, H., Paulk, N., Ranade, A., Dorrell, C., Al-Dhalimy, M., Ellis, E., Strom, S., Kay, M. A., Finegold, M., & Grompe, M. (2007) · Nature Biotechnology · doi:10.1038/nbt1326 · Cited by 835
Self-citationWorldwide epidemiology of neutralizing antibodies to adeno-associated viruses
Calcedo, R., Vandenberghe, L. H., Gao, G., Lin, J., & Wilson, J. M. (2009) · The Journal of Infectious Diseases · doi:10.1086/595830 · Cited by 808
Grimm, D., Lee, J. S., Wang, L., Desai, T., Akache, B., Storm, T. A., & Kay, M. A. (2008) · Journal of Virology · doi:10.1128/jvi.00254-08 · Cited by 696
Self-citationDirected evolution of adeno-associated virus yields enhanced gene delivery vectors
Maheshri, N., Koerber, J. T., Kaspar, B. K., & Schaffer, D. V. (2006) · Nature Biotechnology · doi:10.1038/nbt1182 · Cited by 538
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–453 of 453
AAV vectors tested in perfused human livers
Herzog, R. W., & de Jong, Y. P. (2025) · Nature Biotechnology · doi:10.1038/s41587-024-02539-y · Cited by 1
Vascular-targeted recombinant adeno-associated viral vectors for the treatment of rare diseases
Körbelin, J., Schwaninger, M., & Trepel, M. (2016) · Rare Diseases · doi:10.1080/21675511.2016.1220470 · Cited by 2
Immune System Obstacles to In vivo Gene Transfer with Adeno-Associated Virus Vectors
Büning, H., & Mingozzi, F. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800563-7.00004-x · Cited by 1
Hematopoietic stem cell gene therapy: progress and challenges
Zhang, X., Cheng, T., & Zhang, J. (2017) · Scientia Sinica Vitae · doi:10.1360/n052017-00268 · Cited by 1
Lundstrom, K. H. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15717-2.00049-4 · Cited by 1
Asp, P., Guha, C., Chowdhury, N. R., & Chowdhury, J. R. (2020) · Wiley eBooks · doi:10.1002/9781119436812.ch73 · Cited by 1
Westhaus, A., Cabanes‐Creus, M., Dilworth, K. L., Zhu, E., Gómez, D. S., Navarro, R. G., Amaya, A. K., Scott, S., Kwiatek, M., McCorkindale, A. L., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.28.510021 · Cited by 1
Self-citationAAV Capsid Screening for Translational Pig Research Using a Mouse Xenograft Liver ModelPreprint
Willimann, M., Tiyaboonchai, A., Adachi, K., Li, B., Waldburger, L., Nakai, H., Grompe, M., & Thöny, B. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.29.596409 · Cited by 1
Self-citationAdeno-associated viruses escort nanomaterials to specific cells and tissuesPreprint
Nagao, K., Paniagua, E. V., Lei, K., Beckham, J. L., Worthington, P., Manthey, M., Ye, M., Koehler, F., Kim, Y. J., Malkin, E., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.04.647267 · Cited by 2
Epstein, B. E., Soden, G. M., Incao, A. A., Mylvara, A. V., Flynn, J. R., Ozsolak, F., & Pavan, W. J. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.15.670473 · Cited by 1
Gene Correction Technology and Its Impact on Viral Research and Therapy
Lee, G. H., & Aung, M. M. (2016) · InTech eBooks · doi:10.5772/62231 · Cited by 1
Chemical Modulation of AAV Trafficking
Berry, G. E. (2016) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/dpe3-gy73
Warischalk, J. K. (2015) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/dqdt-1s58
Application of CRISPR/Cas9 in Treating Hepatitis B Virus
Cho, J. (2017) · Journal of Liver Cancer · doi:10.17998/jlc.17.2.111
基于CRISPR/Cas9基因编辑技术的人类遗传疾病基因治疗相关研究进展
门, 可., 段, 醒., 杨, 阳., & 魏, 于. (2017) · Scientia Sinica Vitae · doi:10.1360/n052017-00169
Intravenously administered gene therapy for neuronopathic Gaucher disease
Massaro, G. (2018) · UCL Discovery (University College London)
Modelling and genetic correction of liver genetic diseases
Zabulica, M. (2021) · Figshare
APPLICATION OF RADIOISOTOPES AND IONIZING RADIATION FOR INSECT CONTROL.
Kloft, W., Suess, A., & Haisch, A. (1971) · OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information)
Human Hepatocyte Transduction with Adeno-Associated Virus Vector
Song, Z., Shao, W., Song, L., Pei, X., & Li, C. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2557-6_5
Capsid-mediated chromatin state of the AAV vector genome controls host species rangePreprint
Gonzalez‐Sandoval, A., Tsuji, S., Zhang, F., Hung, K. L., Chang, H. Y., Pekrun, K., & Kay, M. A. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.06.511169
Self-citationGene Therapy in Haemophilia: Updates from Clinical Trials and Insights to Future Technologies
Carter, S. (2022) · EMJ Cardiology · doi:10.33590/emjcardiol/10136425
Tirthal, U. A. (2022) · Journal of Pharmaceutical Negative Results · doi:10.47750/pnr.2022.13.s08.489
“Although the fundamentals of AAV cellular entrance are still unclear, efforts are being made to produce AAV variants with unique and biomedically valuable cell tropisms to enable for successful systemic delivery [8,10].”
BackgroundKwiatek, M., Michalski, A., Abramowicz, K., Rutyna, P., Wasiak, M., Reichert, M., & Lisowski, L. (2023) · Lekarz Wojskowy · doi:10.53301/lw/156374
“The second most effective vectors (AAV2 and AAV3) belong to one clade, and the weakest transducers (AAV4, AAV11 and AAV12) also belong to one clade, a fact that can potentially explain similarity in transduction pattern.”
InfluentialSelf-citationBenyamini, B., Esbin, M. N., Whitney, O. N., Walther, N., & Maurer, A. C. (2023) · doi:10.3791/65572-v
Multistage Carcinogenesis: Cell and Animal Models
Kulesz-Martin, M. F., Ouyang, X., Ramin, S., Barling, A. N., Gallegos, J. R., Liu, Y., & Medler, T. R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.00085-1
Gene Expression and Editing in Mammalian Retinal Ganglion Cells
Tran, N. M., Xu, X., Qi, L. S., & Hu, Y. (2024) · Essentials in ophthalmology/Essentials ophthalmology · doi:10.1007/978-981-99-4436-1_19
Li, L., Qin, R., Liu, Y., Tseng, Y.-S., Zhang, W., Yu, L., Mietzsch, M., Zou, X., Liu, H., Lu, G., et al. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1012260
“Positive selectionin adeno-associatedvirus evolution completely reflect their tissue tropism in humans, as AAV2 and AAV8 previously exhibited similarly variable performance in mouse and human hepatocytes [43].”
BackgroundResultLncRNA: Secret Regulators of Cancer Metabolism
Demirkaya, D. B., & Yalçın, S. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_470
Function of noncoding RNA in regulating cancer cell plasticity
Her, P. H., Lam, M., Zeng, S., & He, H. H. (2024) · Cancer Heterogeneity and Plasticity · doi:10.47248/chp2401020007
Zhu, Y., You, G., Jiang, Y., Yin, K., Wang, R., Li, C., Zhang, X., Yan, Z., Ding, M., Guo, W., et al. (2025) · The FASEB Journal · doi:10.1096/fj.202502602r
“For clinical translation, the selection and evaluation of clinically relevant rAAV variants is imperative [17].”
EvoPRAISE: computationally guided directed evolution for rational AAV capsid engineeringPreprint
Ono, H., Fujino, S., & Sunagawa, G. A. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.02.686002
Progress in research of premetastatic niche in colorectal cancer liver metastasis
Chi, Z.-C. (2025) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v33.i11.847
Species-specific AAVR dominates species-tropism of adeno-associated virus (AAV) vectorsPreprint
Kay, M. A., Jiang, Y., Liu, Y., Jing, Y., Zhang, F., & Lin, A. (2025) · Research Square · doi:10.21203/rs.3.rs-8198480/v1
“For example, AAV-LK03, which was selected from a shu�ed capsid library and selected from a humanized liver mouse model 2 , provided high rates of transduction in primates 3,4 and ultimately in a hemophilia A clinical trial 5 , does not transduce murine liver or cells well 6 .”
Self-citationShin, H.-S., Cho, S.-Y., Kwon, Y., Jung, S.-M., Seo, E. S., Son, Y. M., Kim, E. T., Kim, D., & Kim, K.-D. (2026) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2026.1716928
Llinares, C., Namkung, S., Yip, M., Vales, Á., Olagüe, C., Mauleón, I., Isola, S., Moeini, P., González‐Aseguinolaza, G., Tai, P. W. L., et al. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102899
Characterisation of AAV capsid-specific CD8+ T cell responses in human subjects
Vandamme, C. (2016) · theses.fr (ABES) · doi:10.70675/371e4bbfze69az417bz960azf9db02287546
Computationally guided discovery of Ly6e/LY6E-dependent AAV capsid variants
Ono, H., Fujino, S., & Sunagawa, G. A. (2026) · iScience · doi:10.1016/j.isci.2026.115554
Evolution dirigée de virus adéno-associés pour un transfert de gène efficace dans le système visuel
Planul, A. (2017) · theses.fr (ABES) · doi:10.70675/c9b178a1z8ba4z4451za409z4e80a603376f
Etude de la réponse immunitaire virale préexistante anti-AAV chez l'homme
Xicluna, R. (2019) · theses.fr (ABES) · doi:10.70675/d2f47d7cz4f46z448cz85afz657c9516c86f
Preclinical gene therapy using recombinant AAV vectors in mouse models of two human diseases
Günes, Y. Ö. (2022) · theses.fr (ABES) · doi:10.70675/52c9a808z1652z42c4zae82zc812b95f1723
Directed evolution of adeno associated virus (AAV) for retinal gene therapy
Tekinsoy, M. (2022) · theses.fr (ABES) · doi:10.70675/80e7fd11z0ae7z46ffz8f69zb50f7a34df5a
Mapping AAV capsid sequences to functions through function-guided in silico evolution
Guo, B., Zheng, H., Lin, X., Jiang, H., Mo, A., Wei, H., Zhang, R., Yuan, Y., Wu, Y., Li, H., et al. (2026) · Cell Press Blue · doi:10.1016/j.cpblue.2026.100016 · Cited by 1
Self-citationCapsid Engineering of Adeno-Associated Viruses for Targeted Gene Therapy in Kidney Diseases
Ghaffarzadeh-Esfahani, M., & Gheisari, Y. (2026) · Human Gene Therapy · doi:10.1177/10430342261452215 · Cited by 1
Ramamurthy, R. M., Zheng, W. T., Wachtman, S. E., Diaz, J. H., George, S. K., Simon, T., Zhou, Y., Wan, M., Lu, B., Walker, S. J., et al. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201772
“…their utilization of hepatocyte-specific promoters, based on the assumption that both AAV5 and AAV3b exhibit a pronounced tropism for human hepatocytes, 19,68 and the rationale that the slow turnover of hepatocytes in the adult liver 69 should prolong AAV’s episomal therapeutic gene expression.”
Yin, L. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1016169
Gao, H. X., & Xu, T. (2026) · Biomedicines · doi:10.3390/biomedicines14071426
“To mitigate toxicity, strategies such as capsid engineering (e.g., designing mutants with low hepatic targeting or immune evasion sites) and the use of tissue-specific promoters (e.g., cTnT or Syn1) should be explored, as they could limit transgene leakage [31].”
Distinct YY dinucleotide periodicity in adeno-associated virus DNA
Baumgartl, C., Becker, J., Naber, L., Xu, M., Gerstmann, E., Gonzalez-Calero, J. G., Suppacher, J., Hess, S., Bubeck, F., & Grimm, D. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.07.003
“37 Here, we used this procedure to partially disrupt the inherent periodic pattern on the viral DNA and then to analyze which chimeric sequences are enriched under a specific selection pressure.”
Liver regenerative medicine approaches: Translational strategies for pediatric surgery
Tian, Y., Li, L., Li, X., Lian, H., Chen, Y., & Tam, P. K. H. (2026) · Seminars in Pediatric Surgery · doi:10.1016/j.sempedsurg.2026.151681
NAE1-Dependent Protein Neddylation Preserves Endothelial Identity and Vascular IntegrityPreprint
Zoni, R. N., Tanni, F. Y., Lee, C. M., Cheng, X., Zhu, J., Baki, V. B., Islam, M. S., Li, J., Su, H., & Sun, X. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.27.746884
Gene Therapy Approaches for the Treatment of Phenylketonuria
Martinez, M. A., Young, L. J., Harding, C. O., Schwank, G., & Thöny, B. (2026) · Springer eBooks · doi:10.1007/978-3-032-26690-3_20
Bouquet, C., Tamarit, B., González‐Aseguinolaza, G., Ferrer, V., Valero, S., Douar, A. M., Brossel, A., Fuhr, R., & Combal, J. P. (2026) · Gene Therapy · doi:10.1038/s41434-026-00651-z
Metadata
- Authors
- Lisowski, L., Dane, A. P., Chu, K., Zhang, Y., Cunningham, S. C., Wilson, E. M., Nygaard, S., Grompe, M., Alexander, I. E., & Kay, M. A.
- Affiliations
- Salk Institute for Biological Studies (US)
- Stanford Medicine (US)
- Children's Medical Research Institute (AU)
- Yecuris (United States) (US)
- Oregon Health & Science University (US)
- The University of Sydney (AU)
- Corresponding author
- Kay, Mark A.
- ORCID
- Venue
- Nature
- Published
- 2013-12-25
- Volume
- 506
- Issue
- 7488
- Pages
- 382-386
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3939040
- OpenAlex
- W1981950767
- Cited by
- 450
- References
- 36
- Citations by year
- 2026: 20 · 2025: 28 · 2024: 36 · 2023: 39 · 2022: 45 · 2021: 34 · 2020: 42 · 2019: 36 · 2018: 32 · 2017: 41 · 2016: 35 · 2015: 46 · 2014: 14 · 2013: 1
- FWCI
- 21.18
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Heart, Lung, and Blood Institute (HL064274, HL092096, R01HL092096, R01HL064274)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK048252, DK048252)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- recombinant adeno-associated virus, AAV serotype 2, xenotransplantation, DNA shuffling, gene therapy vectors
- MeSH terms
- Dependovirus, Animals, Capsid, Cells, Cultured, Chimera, Clinical Trials as Topic, Disease Models, Animal, Female, Genetic Vectors, Carcinoma, Hepatocellular, Humans, Liver, Male, Species Specificity, Transduction, Genetic, Genetic Therapy, Transgenes, Hepatocytes, Capsid Proteins, Cell Line, Tumor, Mice, Heterografts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
